ETX fundamentals

e-Therapeutics Plc, is a drug discovery and development company, which engages in the provision of evaluation services to investors and pharmaceutical companies. The company focuses on the therapeutic immune-oncology, addressing drug resistance in targeted cancer therapies and antivirals. It offers the following variety of preclinical stage assets: ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFa; ETS2400, Hedgehog pathway inhibition; and ETS5200, broad spectrum antivirals together with two immuno-oncology checkpoint projects. The company was founded by Malcolm Philip Young on October 15, 2001 and is headquartered in London, the United Kingdom.